Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More

Spotlight

Editas News

September 22, 2014
FierceBiotech names Editas Medicine as one of its Fierce 15 Biotech Companies of 2014 Read More

June 24, 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer Read More

May 14, 2014
2014 NEVY Awards: Editas Medicine Wins Hottest Healthcare Startup Read More

April 25, 2014
Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers Read More

April 15, 2014
Editas Medicine Co-Founder is awarded First Patent for Engineered CRISPR-Cas9 System   Read More

February 13, 2014
Editas Medicine Co-Founder Publishes Key CRISPR Complex Structure in Cell Read More

February 7, 2014
Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science Read More

Publications

August 11, 2014
Nature Methods: Improved vectors and genome-wide libraries for CRISPR screening.     Read More

July 1, 2014
Bioinformatics: Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA).   Read More

June 6, 2014
Cell: Development and Applications of CRISPR-Cas9 for Genome Engineering. Read More